Analyzing OMV Aktiengesellschaft (OTCMKTS:OMVJF) and SWEDISH ORPHAN/S (OTCMKTS:SWTUY)

OMV Aktiengesellschaft (OTCMKTS:OMVJF) and SWEDISH ORPHAN/S (OTCMKTS:SWTUY) are both energy companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares OMV Aktiengesellschaft and SWEDISH ORPHAN/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OMV Aktiengesellschaft	4.25%	8.95%	4.50%
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%

Valuation & Earnings

This table compares OMV Aktiengesellschaft and SWEDISH ORPHAN/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OMV Aktiengesellschaft	$43.86 billion	0.40	$1.68 billion	$5.17	10.49
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76

OMV Aktiengesellschaft has higher revenue and earnings than SWEDISH ORPHAN/S. OMV Aktiengesellschaft is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

OMV Aktiengesellschaft has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, SWEDISH ORPHAN/S has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for OMV Aktiengesellschaft and SWEDISH ORPHAN/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OMV Aktiengesellschaft	0	0	0	1	4.00
SWEDISH ORPHAN/S	0	0	0	0	0.00

Summary

SWEDISH ORPHAN/S beats OMV Aktiengesellschaft on 6 of the 11 factors compared between the two stocks.

About OMV Aktiengesellschaft

OMV Aktiengesellschaft operates as an energy and chemicals company in Austria, Germany, Romania, Norway, Belgium, New Zealand, the United Arab Emirates, the rest of Central and Eastern Europe, the rest of Europe, and internationally. It operates through three segments: Chemicals & Materials, Fuels & Feedstock, and Energy. The company engages in the exploration, development, and production of oil and gas in the regions of Central and Eastern Europe, the Middle East and Africa, the North Sea, and the Asia Pacific; and refining and marketing of fuels and feedstock, as well as supply, marketing, trading, and logistics of gas in Romania and Turkey. In addition, the company provides advanced and circular polyolefin solutions, and base chemicals, as well as engages in the recycling of plastics. It has refineries in Europe, Schwechat, and Burghausen; filling stations in eight European countries; and gas storage facilities in Austria and Germany, as well as a gas-fired power plant in Romania. The company was founded in 1956 and is headquartered in Vienna, Austria.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.